<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03520491</url>
  </required_header>
  <id_info>
    <org_study_id>18-042</org_study_id>
    <nct_id>NCT03520491</nct_id>
  </id_info>
  <brief_title>A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy</brief_title>
  <official_title>A Pilot Study to Evaluate the Safety of Neoadjuvant Nivolumab Alone or in Combination With Ipilimumab for Cisplatin-Ineligible Patients With Muscle Invasive Bladder Cancer (CA209-9DJ)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test if immunotherapy with nivolumab alone or in combination&#xD;
      with ipilimumab is safe and does not delay the planned bladder cancer surgery. The&#xD;
      investigators want to see if treatment with these drugs prior to surgery may decrease the&#xD;
      size of the bladder cancer and thus could help make the surgery more successful.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 25, 2018</start_date>
  <completion_date type="Anticipated">January 2022</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>This is a pilot study designed to evaluate neoadjuvant nivolumab and nivolumab in combination with ipilimumab in patients with muscle-invasive bladder cancer (MIBC) or urothelial cancers of the upper urinary tract (ureter or renal pelvis) [UTUC], who are ineligible for treatment with cisplatin-based chemotherapy. The study is designed with three sequential 15-patient cohorts.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>number of patients who proceed to radical cystectomy and pelvic lymph node dissection (RC-PLND)</measure>
    <time_frame>within 60 days after completion of neoadjuvant nivolumab or nivolumab in combination with ipilimumab for cisplatin-ineligible MIBC, without delays due to treatment-related toxicities or progressive disease</time_frame>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Nivolumab 3 mg/kg on day 1 of each cycle for a total of 5 cycles. Each cycle will be two weeks long and treatment will occur during weeks 0, 2, 4, 6, and 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1 of each cycle, followed by Nivolumab 3 mg/kg on day 22 of each cycle for a total of 2 cycles. Each cycle will be six weeks long. Ipilimumab and Nivolumab will occur on weeks 0 and 6 while Nivolumab alone will occur on weeks 3 and 9.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab 3 mg/kg on day 1 each cycle and Nivolumab 1 mg/kg on day 1 of each cycle for a total of 3 cycles. Each cycle will be three weeks long and treatment will occur during weeks 0, 3, and 6.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ipilimumab 3 mg/kg and Nivolumab 1 mg/kg on day 1, of each cycle, followed by Nivolumab 3 mg/kg on day 22 and Ipilimumab 3mg/kg and Nivolumab 1mg/kg on day 45.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 3 mg/kg or Nivolumab 1 mg/kg</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab 3 mg/kg</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Radical cystectomy</intervention_name>
    <description>RC-PLND is to take place within 60 days from the last dose of treatment.(After week 10 for cohort 1, after week 11 for cohort 2, and after week 9 for cohort 3.)</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort U (UTUC patients) is independent from Cohorts 1 - 3. ( who are cisplatin-ineligible)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed diagnosis of urothelial carcinoma of the bladder. Variant&#xD;
             histology is acceptable if there is a predominant urothelial component.&#xD;
&#xD;
          -  For MUSCLE-INVASIVE UROTHELIAL CANCER OF THE BLADDER (Cohorts 1 - 3):&#xD;
&#xD;
             ° Cystoscopically and radiographically confirmed cT2-4a cN0 cM0 disease. Patients with&#xD;
             cT4a disease invading into the prostatic stroma with no cystoscopic confirmation of&#xD;
             muscle invasion are eligible.&#xD;
&#xD;
          -  For UROTHELIAL CARCINOMA OF THE UPPER URINARY TRACT (URETER OR RENAL PELVIS) (Cohort&#xD;
             U):&#xD;
&#xD;
             °Histologically confirmed high grade urothelial carcinoma of the upper tract and/or&#xD;
             radiographically visible tumor stage T2-T4a N0/x M0 disease with positive selective&#xD;
             urinary cytology. Hydronephrosis associated with tumor on imaging or biopsy will be&#xD;
             considered invasive by definition. (Variant histology is acceptable if there is a&#xD;
             predominant urothelial component)&#xD;
&#xD;
          -  Patients ineligible for cisplatin based on any of the following criteria:&#xD;
&#xD;
               -  Estimated or calculated creatinine clearance ≥ 30ml/min but &lt; 60 ml/min&#xD;
&#xD;
               -  Grade 2 or above audiometric hearing loss (per CTCAE v4.0)&#xD;
&#xD;
               -  Grade 2 or above peripheral neuropathy (per CTCAE v4.0)&#xD;
&#xD;
          -  Availability of tumor specimen block or 30 unstained slides from diagnosis of&#xD;
             muscle-invasive disease. Patients with fewer than 30 slides available may be enrolled&#xD;
             after discussion with the Principal Investigator.&#xD;
&#xD;
          -  Karnofsky performance status ≥ 70%.&#xD;
&#xD;
          -  Medically appropriate candidate for radical cystectomy, as per MSK Attending Urologic&#xD;
             Oncologist&#xD;
&#xD;
          -  Age ≥ 18 years.&#xD;
&#xD;
          -  Required initial laboratory values:&#xD;
&#xD;
               -  Absolute neutrophil count ≥ 1.5 x 10^9/L&#xD;
&#xD;
               -  Platelets ≥ 100 x 10^9/L&#xD;
&#xD;
               -  Bilirubin ≤1.5 times the upper limit of normal (x ULN)&#xD;
&#xD;
               -  Aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 3 x ULN&#xD;
&#xD;
               -  PTT/PT ≤1.5 x ULN or INR &lt; 1.7 x ULN for patients who are not receiving&#xD;
                  therapeutic anticoagulation. Patients receiving therapeutic anticoagulation&#xD;
                  should be on a stable dose.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Prior treatment with systemic chemotherapy for urothelial cancer, including immune&#xD;
             checkpoint inhibitors for non-muscle invasive bladder cancer. (Prior intravesical&#xD;
             treatment such as BCG is allowed.)&#xD;
&#xD;
          -  Prior bladder-directed radiotherapy (exclusion applies only to MIBC Cohorts 1 - 3).&#xD;
&#xD;
          -  Presence of active autoimmune disease, symptoms, or conditions, with the following&#xD;
             exceptions:&#xD;
&#xD;
             °Subjects with type I diabetes mellitus, residual hypothyroidism due to autoimmune&#xD;
             thyroiditis only requiring hormone replacement, skin disorders (such as vitiligo,&#xD;
             psoriasis, or alopecia) not requiring systemic treatment, asymptomatic laboratory&#xD;
             evidence of autoimmune disease (e.g.: +ANA, +RF, anti-thyroglobulin antibodies), or&#xD;
             conditions not expected to recur in the absence of an external trigger are permitted&#xD;
             to enroll.&#xD;
&#xD;
          -  Subjects with a condition requiring systemic treatment with either corticosteroids&#xD;
             (&gt;10 mg daily prednisone equivalent) or other immunosuppressive medications within 14&#xD;
             days of first dose of study drug. Inhaled or topical steroids, and adrenal replacement&#xD;
             steroid doses are permitted in the absence of active autoimmune disease.&#xD;
&#xD;
          -  Unstable angina.&#xD;
&#xD;
          -  New York Heart Association (NYHA) Grade II or greater congestive heart failure.&#xD;
&#xD;
          -  History of myocardial infarction within 6 months.&#xD;
&#xD;
          -  History of stroke within 6 months.&#xD;
&#xD;
          -  Evidence of bleeding diathesis or coagulopathy. Therapeutic anticoagulation is&#xD;
             permitted, but patients must be on a stable dose.&#xD;
&#xD;
          -  Major surgical procedure within 28 days prior to the study. (Transurethral resection&#xD;
             of bladder tumor is permitted&#xD;
&#xD;
          -  Serious, non-healing wound, ulcer, or bone fracture.&#xD;
&#xD;
          -  Other prior malignancy active within the previous 2 years except for local or&#xD;
             organ-confined early stage cancer that has been definitively treated with curative&#xD;
             intent or does not require treatment, does not require ongoing treatment, has no&#xD;
             evidence of active disease, and has a negligible risk of recurrence and is therefore&#xD;
             unlikely to interfere with the endpoints of the study.&#xD;
&#xD;
          -  Subjects who have received prior therapy with any T cell co-stimulation or checkpoint&#xD;
             pathways such as anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4, anti-CD137; or other&#xD;
             medicines specifically targeting T cells are prohibited. Prior IL-2 is permitted.&#xD;
&#xD;
          -  Prior therapy with intravesical BCG within 6 weeks of treatment.&#xD;
&#xD;
          -  Positive test for hepatitis B virus (HBV) using HBV surface antigen (HBV sAg) test or&#xD;
             positive test for hepatitis C virus (HCV) using HCV ribonucleic acid (RNA) or HCV&#xD;
             antibody test indicating acute or chronic infection.&#xD;
&#xD;
          -  Known history of testing positive for human immunodeficiency virus (HIV) or known&#xD;
             acquired immunodeficiency syndrome (AIDS).&#xD;
&#xD;
          -  History of allergy to study drug component or history of severe hypersensitivity&#xD;
             reaction to any monoclonal antibody.&#xD;
&#xD;
          -  Women who are breastfeeding or pregnant as evidenced by a positive pregnancy test&#xD;
             within 14 days of first dose.&#xD;
&#xD;
          -  Male subjects who are unwilling to use contraception during the treatment and for at&#xD;
             least 31 weeks after the last dose of study treatment (5 half-lives of study drug plus&#xD;
             90 days duration of sperm turnover).&#xD;
&#xD;
          -  Women of childbearing potential (WOCBP) not using a medically acceptable means of&#xD;
             contraception throughout the study treatment and for at least 23 weeks following the&#xD;
             last dose of study treatment (5 half-lives of study drug plus 30 days duration of&#xD;
             ovulatory cycle).&#xD;
&#xD;
               -  WOCBP are defined as those who have experienced menarche and who have not&#xD;
                  undergone successful surgical sterilization (hysterectomy, bilateral tubal&#xD;
                  ligation, or bilateral oophorectomy) or are not postmenopausal. Post-menopausal&#xD;
                  is defined as:&#xD;
&#xD;
               -  Amenorrhea ≥ 12 consecutive months without another cause, or&#xD;
&#xD;
               -  For women with irregular menstrual periods and on hormone replacement therapy&#xD;
                  (HRT), a documented serum follicle stimulating hormone (FSH) level &gt; 35 mIU/mL&#xD;
&#xD;
          -  Subjects who are compulsorily detained for treatment of either a psychiatric or&#xD;
             physical (e.g., infectious disease) illness.&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Yuen Teo, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Min Yuen Teo, MD</last_name>
    <phone>646-888-4867</phone>
    <email>teom@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Jonathon Rosenberg, MD</last_name>
    <phone>646-888-4741</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Basking Ridge (All Protocol Activities)</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yuen Teo, MD</last_name>
      <phone>646-888-4867</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Monmouth (All Protocol Activities)</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yuen Teo, MD</last_name>
      <phone>646-888-4867</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen (All Protocol Activities)</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yuen Teo, MD</last_name>
      <phone>646-888-4867</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack (All protocol activities)</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yuen Teo, MD</last_name>
      <phone>646-888-4867</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Westchester (All Protocol Activities)</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yuen Teo, MD</last_name>
      <phone>646-888-4867</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center (All Protocol Activities)</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yuen Teo, MD</last_name>
      <phone>646-888-4867</phone>
    </contact>
    <contact_backup>
      <last_name>Jonathan Rosenberg, MD</last_name>
      <phone>646-888-4741</phone>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau (All protocol activities)</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Min Yuen Teo, MD</last_name>
      <phone>646-888-4867</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 26, 2018</study_first_submitted>
  <study_first_submitted_qc>April 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 9, 2018</study_first_posted>
  <last_update_submitted>March 29, 2021</last_update_submitted>
  <last_update_submitted_qc>March 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Nivolumab</keyword>
  <keyword>Ipilimumab</keyword>
  <keyword>18-042</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

